Press Releases

Conference Call & Webcast Scheduled for Wednesday, May 15, at 8:30am Eastern Time GAITHERSBURG, Md. , May 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2019 and

GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2019 before the market open and host a conference call on Wednesday, May 15,

Dr. Sybil Tasker to present on April 16 at 12:55pm Eastern Time GAITHERSBURG, Md. , April 11, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress being held in Washington D.C.

Conference call and webcast scheduled for tomorrow, Tuesday, April 2, at 8:30 am Eastern Time GAITHERSBURG, Md. , April 01, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December 31, 2018 ,

GAITHERSBURG, Md. , March 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the year ended December 31, 2018 before the market open and host a conference call on Tuesday, April 2, 2019

Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSBURG, Md. , March 19, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company,

GAITHERSBURG, Md. , March 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg , Ph.D., President and Chief Executive Officer, and Will Brown , Acting Chief Financial Officer, will provide a corporate overview at

GAITHERSBURG, Md. , March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-funded units receiving gross proceeds of $14 million .

GAITHERSBURG, Md. , March 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two institutional investors for the purchase of common units and pre-funded units for a combined total of

GAITHERSBURG, Md. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be presented on April 12, 2019 at The International Liver Congress sponsored by